01 — At a Glance
The Ambitious CDMO That’s Running on Fumes & Spreadsheet Projections
- 52-Week High / Low₹322 / ₹154
- Q3 FY26 Revenue₹720 Cr
- Q3 FY26 PAT₹-13 Cr
- EPS (TTM)₹7.58
- 3-Month Return-38.2%
- Book Value / Share₹406
- Price to Book0.39x
- ROE (TTM)-0.32%
- Net Debt / EBITDA3.92x
- Credit RatingIND A/Negative
Flash Summary: DCAL reported Q3 PAT of ₹-13 crore — yes, they lost money last quarter. Revenue of ₹720 crore is growing at 5.5% YoY, which sounds fine until you realise EBITDA margins collapsed from 22.8% to 15.7%, and Ind-Ra just downgraded their NCDs from A+ Stable to A/Negative on February 18, 2026. The stock has crashed 48.5% in six months. Management is still going on earnings calls talking about ₹500 crore India revenue targets and ADC powerhouses. Someone should tell them the French facility is running at 20% capacity and bleeding cash. But first, let’s understand how a company with a ₹22 lakh crore addressable market in global pharma CDMO can’t seem to actually make money.
02 — Introduction
The CDMO That Promised The Moon. And Built Half a Spaceship.
Dishman Carbogen Amcis Limited (DCAL) is a Contract Research and Manufacturing Services (CRAMS) provider. Translation: you’re a big pharma company trying to develop a drug, you give DCAL a briefcase full of molecules, and they turn it into a commercial pill. It’s a high-touch, high-margin business — theoretically. DCAL operates 25 manufacturing plants across India, Switzerland, France, the UK, Netherlands, and China, all blessed by the FDA, PMDA, EDQM, and a alphabet soup of other regulatory bodies.
Here’s the plot twist: in 2017, the European regulators found some GMP compliance issues at their Bavla facility in Gujarat. The audits were so brutal that DCAL spent the next five years in the regulatory dungeon, unable to take on new customers, unable to ramp capacity, unable to do anything except fix the damn facility. Hundreds of millions were spent. Certifications were painstakingly rebuilt. It was supposed to be a comeback story.
Fast forward to Q3 FY26: they finally got their US FDA approval in May 2024, EDQM cleared them in February 2024, and PMDA blessed them in August 2023. All clear. The comeback is on. Except the moment they got access back to the market, they realised: everyone else had already moved on. Competitors had filled the void. Pricing had compressed. And now DCAL is trying to wrestle back market share while simultaneously running a brand-new facility in France that was supposed to be a margin powerhouse but is instead a margin crematorium.
The Concall Said (Feb 2026): “More RFPs, more projects secured… increased interest in late-phase projects.” Translation: we’re winning some deals now, but the deals we’re winning are cheap. The really profitable work (blockbuster late-phase manufacturing) is dominated by the players who never lost access — Catalent, Lonza, Samsung BioLogics. DCAL is competing on cost and capability, not on relationships.
03 — Business Model: The Casio of Global CDMOs
You Make Good Watches. But Sony Already Has The Cool Factor.
Members get full access to every article.
